Like this article?
Get your free daily medical news from Physician's First Watch.
Tinzaparin Associated with Increased Mortality Risk in Elderly Patients with Renal Insufficiency
Tinzaparin (Innohep), a low-molecular-weight heparin, may be associated with an increased mortality risk in patients aged 70 or older who have renal insufficiency, the FDA cautioned on Tuesday.
The warning follows the early termination of a European study testing the safety of tinzaparin versus unfractionated heparin to treat deep venous thrombosis, pulmonary emboli, or both in elderly patients with renal insufficiency. The trial was stopped in February because of a higher rate of all-cause mortality in patients given tinzaparin, compared with unfractionated heparin (13% vs. 5%).
LINK(S):
FDA alert (Free)
Published in Physician's First Watch December 3, 2008
Your Remark:
To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.